SEC Tracker
Get the app

KLA KLAC

KLA Q1 FY25: revenue $2.8B; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers KLA reported for Q1 FY25, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$2.8BNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$945.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$0.00No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported $7.0110-Q income statement, on EDGAR
  4. Cash and cash equivalents$2.0BNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations$995.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when KLA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3827 and related industry codes: the same peer list as the financial tables.

  1. Thermo Fisher Scientific TMO public float $154.0B, Jun 27, 2025
  2. Danaher DHR public float $125.9B, Jun 30, 2025
  3. Trane Technologies TT public float $97.2B, Jun 30, 2025
  4. Roper Technologies ROP public float $60.8B, Jun 30, 2025
  5. Ametek AME public float $41.8B, Jun 30, 2025